IL126152A0 - Recombinant adenoviral vectors for human tumor gene therapy - Google Patents
Recombinant adenoviral vectors for human tumor gene therapyInfo
- Publication number
- IL126152A0 IL126152A0 IL12615297A IL12615297A IL126152A0 IL 126152 A0 IL126152 A0 IL 126152A0 IL 12615297 A IL12615297 A IL 12615297A IL 12615297 A IL12615297 A IL 12615297A IL 126152 A0 IL126152 A0 IL 126152A0
- Authority
- IL
- Israel
- Prior art keywords
- gene therapy
- human tumor
- adenoviral vectors
- recombinant adenoviral
- tumor gene
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 238000001415 gene therapy Methods 0.000 title abstract 2
- 239000013598 vector Substances 0.000 title 1
- 241000700605 Viruses Species 0.000 abstract 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 230000002950 deficient Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9603207A FR2746110B1 (fr) | 1996-03-14 | 1996-03-14 | Methode de traitement par therapie genique des tumeurs humaines et virus recombinants correspondants |
| PCT/FR1997/000435 WO1997034009A1 (fr) | 1996-03-14 | 1997-03-12 | Vecteurs adenoviraux recombinants pour la therapie genique des tumeurs humaines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL126152A0 true IL126152A0 (en) | 1999-05-09 |
Family
ID=9490181
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL12615297A IL126152A0 (en) | 1996-03-14 | 1997-03-12 | Recombinant adenoviral vectors for human tumor gene therapy |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20030082150A1 (de) |
| EP (1) | EP0889969B1 (de) |
| JP (1) | JP2000507229A (de) |
| KR (1) | KR19990087718A (de) |
| CN (1) | CN1218512A (de) |
| AT (1) | ATE309382T1 (de) |
| AU (1) | AU732288B2 (de) |
| BR (1) | BR9707994A (de) |
| CA (1) | CA2248612A1 (de) |
| CZ (1) | CZ295967B6 (de) |
| DE (1) | DE69734574T2 (de) |
| DK (1) | DK0889969T3 (de) |
| ES (1) | ES2252779T3 (de) |
| FR (1) | FR2746110B1 (de) |
| HU (1) | HUP9902150A3 (de) |
| IL (1) | IL126152A0 (de) |
| NO (1) | NO984052D0 (de) |
| SK (1) | SK124698A3 (de) |
| WO (1) | WO1997034009A1 (de) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998015638A2 (en) * | 1996-10-07 | 1998-04-16 | Ludwig Institute For Cancer Research | Replication-defective adenoviruses for cancer immunotherapy |
| CA2721011A1 (en) | 1999-10-22 | 2001-05-03 | Aventis Pasteur Limited | Modified gp100 and uses thereof |
| US7851212B2 (en) * | 2000-05-10 | 2010-12-14 | Sanofi Pasteur Limited | Immunogenic polypeptides encoded by MAGE minigenes and uses thereof |
| DE60238044D1 (de) * | 2001-03-27 | 2010-12-02 | Univ New York | Tumortherapie mit vektoren auf sindbis virus-basis |
| US7786278B2 (en) | 2002-04-09 | 2010-08-31 | Sanofi Pasteur Limited | Modified CEA nucleic acid and expression vectors |
| US20060073123A1 (en) * | 2002-04-30 | 2006-04-06 | Jie Mi | Adenovirus vectors for immunotherapy |
| CN1327000C (zh) * | 2002-09-06 | 2007-07-18 | 中国人民解放军军事医学科学院基础医学研究所 | 靶向黑色素瘤的可复制性腺病毒穿梭载体及腺病毒 |
| WO2004037284A1 (en) * | 2002-10-22 | 2004-05-06 | Sanofi Pasteur Limited | Anti-cancer vaccines and high-dose cytokines as adjuvants |
| US8562970B2 (en) * | 2003-10-08 | 2013-10-22 | Sanofi Pasteur Limited | Modified CEA/B7 vector |
| CA3115891A1 (en) | 2013-03-14 | 2014-09-25 | Salk Institute For Biological Studies | Oncolytic adenovirus compositions |
| DK3198009T3 (da) | 2014-09-24 | 2021-11-22 | Salk Inst For Biological Studi | Onkolytiske tumorvira og anvendelsesfremgangsmåder |
| EP3390645B1 (de) | 2016-02-23 | 2022-09-14 | Salk Institute for Biological Studies | Exogene genexpression eines therapeutischen adenovirus mit geringem einfluss auf die virale kinetik |
| JP7054527B2 (ja) | 2016-02-23 | 2022-04-14 | ソーク インスティテュート フォー バイオロジカル スタディーズ | アデノウイルスの複製動態を測定するための高スループットアッセイ |
| CN110062630A (zh) | 2016-12-12 | 2019-07-26 | 萨克生物研究学院 | 肿瘤靶向合成腺病毒及其用途 |
| CA3096099A1 (en) | 2018-04-09 | 2019-10-17 | Salk Institute For Biological Studies | Oncolytic adenovirus compositions with enhanced replication properties |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5342774A (en) * | 1991-05-23 | 1994-08-30 | Ludwig Institute For Cancer Research | Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1 |
| US6235525B1 (en) * | 1991-05-23 | 2001-05-22 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof |
| US5620886A (en) * | 1993-03-18 | 1997-04-15 | Ludwig Institute For Cancer Research | Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2 |
| NZ269156A (en) * | 1993-07-13 | 1996-03-26 | Rhone Poulenc Rorer Sa | Defective recombinant adenovirus vector incapable of replicating autonomously in a target cell and its use in gene therapy |
-
1996
- 1996-03-14 FR FR9603207A patent/FR2746110B1/fr not_active Expired - Fee Related
-
1997
- 1997-03-12 CN CN97193960A patent/CN1218512A/zh active Pending
- 1997-03-12 EP EP97914375A patent/EP0889969B1/de not_active Expired - Lifetime
- 1997-03-12 SK SK1246-98A patent/SK124698A3/sk unknown
- 1997-03-12 CA CA002248612A patent/CA2248612A1/fr not_active Abandoned
- 1997-03-12 US US09/125,887 patent/US20030082150A1/en not_active Abandoned
- 1997-03-12 IL IL12615297A patent/IL126152A0/xx unknown
- 1997-03-12 ES ES97914375T patent/ES2252779T3/es not_active Expired - Lifetime
- 1997-03-12 DE DE69734574T patent/DE69734574T2/de not_active Expired - Fee Related
- 1997-03-12 KR KR1019980707186A patent/KR19990087718A/ko not_active Ceased
- 1997-03-12 JP JP9532334A patent/JP2000507229A/ja not_active Ceased
- 1997-03-12 HU HU9902150A patent/HUP9902150A3/hu unknown
- 1997-03-12 DK DK97914375T patent/DK0889969T3/da active
- 1997-03-12 BR BR9707994A patent/BR9707994A/pt not_active Application Discontinuation
- 1997-03-12 WO PCT/FR1997/000435 patent/WO1997034009A1/fr not_active Ceased
- 1997-03-12 AU AU21641/97A patent/AU732288B2/en not_active Ceased
- 1997-03-12 AT AT97914375T patent/ATE309382T1/de not_active IP Right Cessation
- 1997-03-12 CZ CZ19982915A patent/CZ295967B6/cs unknown
-
1998
- 1998-09-03 NO NO984052A patent/NO984052D0/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| KR19990087718A (ko) | 1999-12-27 |
| ATE309382T1 (de) | 2005-11-15 |
| AU2164197A (en) | 1997-10-01 |
| HUP9902150A2 (hu) | 1999-11-29 |
| DK0889969T3 (da) | 2006-03-27 |
| WO1997034009A1 (fr) | 1997-09-18 |
| CN1218512A (zh) | 1999-06-02 |
| ES2252779T3 (es) | 2006-05-16 |
| JP2000507229A (ja) | 2000-06-13 |
| EP0889969A1 (de) | 1999-01-13 |
| DE69734574D1 (de) | 2005-12-15 |
| CZ295967B6 (cs) | 2005-12-14 |
| FR2746110B1 (fr) | 1998-04-17 |
| NO984052L (no) | 1998-09-03 |
| BR9707994A (pt) | 1999-07-27 |
| CA2248612A1 (fr) | 1997-09-18 |
| EP0889969B1 (de) | 2005-11-09 |
| NO984052D0 (no) | 1998-09-03 |
| SK124698A3 (en) | 1999-05-07 |
| US20030082150A1 (en) | 2003-05-01 |
| HUP9902150A3 (en) | 2000-12-28 |
| AU732288B2 (en) | 2001-04-12 |
| DE69734574T2 (de) | 2006-07-13 |
| CZ291598A3 (cs) | 1998-12-16 |
| FR2746110A1 (fr) | 1997-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL126152A0 (en) | Recombinant adenoviral vectors for human tumor gene therapy | |
| TW581808B (en) | Compounds for immunotherapy of prostate cancer and methods for their use | |
| MY119276A (en) | Pharmaceutical composition for immunomodulation based on peptides and adjuvants | |
| WO1999033869A3 (en) | Compounds for immunotherapy and diagnosis of breast cancer and methods for their use | |
| NZ516381A (en) | Lung tumor proteins in the therapy and diagnosis of lung cancer | |
| IL145731A0 (en) | A polypetide containing an immunogenic portion of a breast tumor protein and pharmaceutical compositions containing the same | |
| WO1998037093A3 (en) | Compounds for immunotherapy of prostate cancer and methods for their use | |
| HUT72558A (en) | Defective adenovirus vectors and use thereof in gene therapy | |
| EP1090924B8 (de) | Von cyclophilin b abstammende tumorantigen-peptide | |
| IL138330A0 (en) | Polynucleotides, polypeptides and pharmaceutical compositions for treating lung cancer | |
| UA66417C2 (en) | Recombinant adenovirus affecting canines, pharmaceutical composition | |
| PL314239A1 (en) | Recombinated adenovirus vector and method of using it | |
| AU2001287639A1 (en) | Trp8, trp9 and trp10, markers for cancer | |
| AUPN568095A0 (en) | Anti-Galalpha(1,3)Gal antibody binding peptides | |
| AU2003242305A1 (en) | Hla-a24-restricted cancer antigen peptide | |
| WO1998037095A3 (en) | Recombinant pox virus for immunization against muc1 tumor-associated antigen | |
| CA2234263A1 (fr) | Composition pharmaceutique contre les tumeurs et infections a papillomavirus | |
| NO953684L (no) | Fremgangsmåte for fremstilling av kreftvaksiner | |
| WO1999032516A3 (en) | Pharmaceutical compositions containing the long pentraxin ptx3 | |
| IL146125A0 (en) | Novel quinones as disease therapies | |
| EP1455840A4 (de) | Behandlung von krebs bei menschen mit adenovirus-vektor tnf-alpha | |
| GR3024379T3 (en) | Peptides with organo-protective activity, the process for preparing them and their use in therapy | |
| IL114382A (en) | Lymphotoxin for use as a medicament for cancer therapy and use thereof in the manufacture of such medicament | |
| AR019844A1 (es) | Polipeptidos composicion farmaceutica, procedimiento para preparar dicha composicion metodo para tratar y prevenir el cancer y metodo para inhibir elcrecimiento de celulas tumorales | |
| AU1991901A (en) | Pharmaceutical composition for treating and preventing human tumors, which express the tumor antigen mucin and/or the carcinoembryonic antigen (cea), and the use thereof |